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Abstract
The Pharmaceutical Benefits Scheme (PBS) grew by 8% in 2003–04; a slower rate than the 12.0%
pa average growth over the last decade. Nevertheless, the sustainability of the Scheme remained
an ongoing concern given an aging population and the continued introduction of useful (but
increasingly expensive) new medicines. There was also concern that the Australia-United States
Free Trade Agreement could place further pressure on the Scheme. In 2003, as in 2002, the
government proposed a 27% increase in PBS patient co-payments and safety-net thresholds in
order to transfer more of the cost of the PBS from the government to consumers. While this
measure was initially blocked by the Senate, the forthcoming election resulted in the Labor Party
eventually supporting this policy. Recommendations of the Pharmaceutical Benefits Advisory
Committee to list, not list or defer a decision to list a medicine on the PBS were made publicly
available for the first time and the full cost of PBS medicines appeared on medicine labels if the price
was greater than the co-payment. Pharmaceutical reform in Victorian public hospitals designed to
minimise PBS cost-shifting was evaluated and extended to other States and Territories. Programs
promoting the quality use of medicines were further developed coordinated by the National
Prescribing Service, Australian Divisions of General Practice and the Pharmacy Guild of Australia.
The extensive uptake of computerised prescribing software by GPs produced benefits but also
problems. The latter included pharmaceutical promotion occurring at the time of prescribing,
failure to incorporate key sources of objective therapeutic information in the software and gross
variation in the ability of various programs to detect important drug-drug interactions. These issues
remain to be tackled.
Review
This paper reviews the growth of the Pharmaceutical Ben-
efits Scheme (PBS) during 2002–03; concerns about the
sustainability of the Scheme, the government's response,
a potential new threat that emerged and issues that
remain to be tackled.
The growth and sustainability of the PBS
From March 2003 to March 2004, a total of $5.8 billion
was spent on prescription medicines subsidised under the
PBS. Of this, $4.89 billion (84%) was paid by the Com-
monwealth, the remaining $0.91 billion through patient
co-payments [1]. In comparison, in 2002–03, the Com-
monwealth spent $7.24 billion on public hospital services
[2] and $8.17 billion on medical and diagnostic services
(through Medicare benefits) [3]. Although the PBS is the
smallest of these components of Commonwealth expend-
iture, it has the highest average annual growth rate over
the last decade (around 12% pa), compared to 6% pa for
public hospital services, and 5% pa for medical services.
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At these rates, by 2011 the Commonwealth would be
spending more on subsidised pharmaceuticals than it
would spend on either public hospital or medical services,
and by 2022, more on pharmaceuticals than both public
hospital and medical services together. Such projections
make the sustainability of the PBS a major concern, espe-
cially given an aging population and the continued intro-
duction of useful (but increasingly expensive) new
medicines [4]. While the growth rate of the PBS has
slowed over the last two years (10% during March 2002–
03 and 8% from March 2003–04) the past history of PBS
expenditure shows considerable fluctuations over the
years. These fluctuations are caused by expensive but val-
uable new drugs coming onto the Scheme, more cost-
effective generic drugs replacing older drugs whose patent
has expired and administrative changes, such as increased
patient co-payments, transiently reducing usage.
The government's response
In 2003, as in 2002, the government proposed a 27%
increase in PBS patient co-payments and safety-net thresh-
olds in order to transfer more of the cost of the PBS from
the government to consumers. Once again this measure
was rejected by Labor and other opposition parties in the
Senate because of concern that such increases would
impact on equitable access to necessary medicines [5].
Regardless, the government continued to argue that with-
out increased patient contributions (and patient restraint)
the PBS would become unsustainable.
By mid 2004, the Labor party was faced with an impend-
ing Federal election and had serious trouble costing its tax
and spending promises. As a consequence, Labor aban-
doned their previous principled stand in the Senate of
blocking the government's proposed increase in PBS
copayments and safety-net thresholds [6] arguing that
they needed the additional $1.1 billion to spend on elec-
tion promises [7]. They also stated that, if returned to gov-
ernment, a substantial proportion of the $1.1 billion
might be achieved through administrative reforms to the
PBS and savings achieved by the use of cheaper generic
drugs as expensive drugs moving off patent. Not surpris-
ingly, consumer and public health groups were appalled
with this Labor "back-flip" while the Greens and Demo-
crats said the decision was a disgrace [8]. Labor said the
decision was difficult but necessary.
Several other measures were introduced by the govern-
ment in order to improve the community's understanding
of PBS processes and costs. From June 2003, all recom-
mendations of the Pharmaceutical Benefits Advisory
Committee (PBAC) to list, not list or defer a decision to
list a medicine on the PBS were made publicly available
on the PBS website [9]. Unfortunately, only summary
information was provided; commercial-in-confidence
concerns of pharmaceutical manufacturers precluded
making more detailed information available, such as cost-
effectiveness data, on which PBAC based its decision.
From 1 August 2003 the full cost of PBS medicines
appeared on medicine labels if the price was greater than
the co-payment. The full cost included what the consumer
has paid and the amount that is paid through the PBS. The
aim was to help people understand what medicines really
cost and how the PBS helps make medicines affordable
for all. In addition, the government commissioned a $24
million advertising campaign that emphasised that
patient responsibility was, "the prescription for a healthy
PBS". Critics noted that by neglecting to inform the public
that pharmaceutical marketing and inappropriate pre-
scribing habits of doctors also produced pressures on the
PBS, the campaign missed an opportunity to initiate a
more balanced and constructive debate about the viability
of the PBS [10].
During the year under review, pharmaceutical reforms
designed to stop PBS cost-shifting in Victorian public hos-
pitals were evaluated [11]. The reforms were a joint initia-
tive of Victorian Department of Human Services (DHS)
and the Australian Government Department of Health
and Ageing (DoHA). Since the early 1990s there had been
increasing cost pressures on State and Territory funded
public hospitals. Their response included restricting drug
supplies to discharged patients, often to only two or three
days of treatment. Patients then needed to see their GP to
obtain a PBS prescription to cover their needs. The effect
was to "cost shift" pharmaceutical supplies from the State
and Territories to the Australian Government. The reforms
trialed in Victoria allowed public hospital doctors to write
PBS prescriptions for both outpatients and discharged
inpatients. They also allowed PBS access to a group of can-
cer chemotherapy drugs for use by day-admitted patients
and outpatients. The qualitative evaluation undertaken
was generally positive although it noted the reforms had
increased the administrative work of both doctors and
pharmacists. There was also concern that PBS rules
(designed for general practice) were not always appropri-
ate for specialised public hospitals. The Society of Hospi-
tal Pharmacists of Australia supported the need to modify
PBS procedures to take into account public hospital exper-
tise but also noted the need for more integration of med-
icines funding [12,13]. Subsequently, the Victorian
reforms are being implemented in other States and Terri-
tories.
Programs promoting the quality use of medicines (QUM)
were further developed throughout 2002–03. Specific
programs were coordinated by the National Prescribing
Service (NPS), Australian Divisions of General Practice
and the Pharmacy Guild of Australia.Australia and New Zealand Health Policy 2005, 2:2 http://www.anzhealthpolicy.com/content/2/1/2
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The NPS was set up in 1999 with government funding but
with an independent Board of Directors in order to pro-
vide unbiased educative activities to assist health practi-
tioners (and more recently consumers) to use medicines
wisely. Evaluation of NPS activities has consistently
shown that spending money on targeted QUM interven-
tions can save considerably more money on the PBS by
reducing inappropriate prescribing. It was estimated that
NPS activities during the period 1 July 2000 to 30 June
2002 generated PBS savings in the range of $55.6 million
to $83.9 million through the following prescribing inter-
vention programs: antibiotics in primary care; peptic ulcer
management; management of dyspepsia; COX-2 selective
NSAIDs; managing hypertension; and managing dyslipi-
daemia [14].
In 2003, the NPS received an additional allocation of gov-
ernment money to provide educational material about
drugs newly listed on the PBS (the RADAR project). The
latter was in response to considerable evidence that inten-
sive pharmaceutical promotion at the time of PBS listing
was associated with drugs being prescribed for broader
indications than those indicated in the PBS listing (caus-
ing so-called PBS "leakage" or "blow-outs") [15]. How-
ever, the 2003 NPS educational budget of $12.5 million
needs to be compared with the estimated $1.0 billion pro-
motional budget of the Australian pharmaceutical indus-
try [16].
The Enhanced Divisional Quality Use of Medicines
(EDQUM) program was a 1999–2000 Federal Budget ini-
tiative, originally announced as the Incentives for Quality
Prescribing (IQP) program. The program offered Divi-
sions of General Practice (Divisions) a proportion of
monies saved if Divisional QUM activities improved pre-
scribing and lowered PBS costs. The Divisions were
allowed to use any savings made for a range of primary
health care activities. The program evolved significantly
due to feedback from the medical profession. It was
implemented on a pilot basis in thirteen Divisions on 1
July 2002. Under the program, Divisions were encouraged
to invest their own resources in a range of drug utilisation
data collection and/or education related activities. Activi-
ties were implemented in close consultation with the NPS
and focused on one or more of the following target drug
groups: antibiotics, peptic ulcer drugs and cardiovascular
drugs.
An evaluation of the pilot EDQUM project was under-
taken in early 2004 [17]. Barriers to implementation
included perceptions that the program was primarily
focused on reducing pharmaceutical costs to government;
limited capacity of existing prescribing software systems
to extract drug utilisation data; and the need for Divisions
to take a commercial risk in developing their EDQUM ini-
tiatives (due to the absence of up-front funding) which
limited their capacity to systematically implement a com-
prehensive range of strategies. Program achievements
included the development of a wide range of shared
resource material [18] and the creation (by some Divi-
sions in association with software vendors) of data extrac-
tion tools. The latter have allowed a small number of
practices to gain access to comprehensive information
from which further initiatives to improve quality or
change practices can evolve. The evaluation report recom-
mended that standards should be established for prescrib-
ing software so that comparable data could be extracted
from different systems to facilitate comparison of individ-
ual prescribing practice with evidence based guidelines. It
also noted the difficulties of attributing any cost-savings
in the PBS to Divisional activities. Following this report,
the Government supported a four year extension to the
EDQUM program in the 2003–2004 Budget.
The Third Community Pharmacy Agreement between the
Government and the Pharmacy Guild of Australia (1 July
2000 to 30 June 2005) also provided a range of QUM
activities over the year in question including medication
reviews of problem patients (conducted at the request of
GPs), quality care pharmacy programs and the provision
of consumer medicine information [19].
A potential new threat that emerged
In 2003–2004 the PBS became caught up in negotiations
concerning the Australia-United States Free Trade Agree-
ment (AUSFTA). This saga has been extensively reported
elsewhere [20,21]. The government remained adamant
that the AUSFTA provisions concerning the PBS were
benign and would also increase the transparency of PBAC
decision-making. Others were concerned that the AUSFTA
contained major concessions to the US pharmaceutical
industry that undermined the egalitarian principles and
operation of the PBS and had the potential to increase the
costs of medicinal drugs to Australian consumers. Time
will tell who is right.
Issues still to be tackled
The EDQUM project highlighted the needs for software
standards in order to extract comparable drug utilisation
data from different prescribing systems. The need for pre-
scribing software standards has also been raised in con-
nection with three other issues of relevance to the PBS:
pharmaceutical promotion, independent therapeutic
information and drug-drug interaction checking.
The uptake of computers by Australian general practition-
ers (GPs) was stimulated by the Australian government in
1999. A one-off grant of around $10,000 was offered to
those practices that purchased a computer, acquired inter-
net connectivity (an E-mail address) and promised to useAustralia and New Zealand Health Policy 2005, 2:2 http://www.anzhealthpolicy.com/content/2/1/2
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computer prescribing software to write the majority of
their prescriptions. This increased the numbers of GPs
writing prescriptions with the aid of a computer from
around 50% in 1999 to more than 90% in 2004 [22]. Leg-
ible, printed prescriptions have been one of a number of
positive outcomes of this initiative. However, new prob-
lems emerged.
One software vendor (Health Communication Network
Ltd.) became the dominant market leader because its
business model relied on pharmaceutical promotion to
heavily subsidise the cost of GPs purchasing and updating
its prescribing software (Medical Director™). This business
model facilitated software uptake but also resulted in
advertisements for the latest and most expensive drugs
appearing on the computer screen at the time of prescrib-
ing (and elsewhere). GPs using this software package were
shown to prescribe more antibiotics per patient than
those who wrote 'scripts manually. It was suggested that
this may have been due to default settings in the software
automatically writing in the maximum number of repeat
prescriptions allowed.[23] Another default option in this
software was the automatic production of a, "Do not sub-
stitute generic drugs" message on the prescription. The lat-
ter was eventually changed by the government amending
regulation 19(5) of the National Health (Pharmaceutical
Benefits) Regulations 1960 [24].
However, the issue of pharmaceutical promotion in pre-
scribing software has yet to be tackled. Pharmaceutical
promotion has never been allowed on government sup-
plied 'script pads. It is hard to understand why it was
allowed on the computerised equivalent. Pharmaceutical
promotion distorts the information flow to physicians by
selectively promoting the benefits of the latest and most
expensive drugs. It provides minimal information about
drug side-effects, contra-indications and opportunity
costs. Cost-effective generic drugs are rarely promoted and
non-drug solutions usually not at all. Pharmaceutical pro-
motion has clearly been shown to influence physician's
prescribing [25] and has resulted in cost-blow outs on the
PBS due to "leakage" of prescribing away from cost-effec-
tive indications approved by PBAC [26]. In addition,
pharmaceutical promotion in prescribing software, occur-
ring at the time of physician decision making, is likely to
be much more influential than promotion in medical
journals, gimmicks and give-ways. As a consequence, sev-
eral medical and consumer organisations have advocated
further amendment of the National Health (Pharmaceuti-
cal Benefits) Regulations 1960, Part V, Regulation 19, to
prohibit prescribing software from displaying pharmaceu-
tical advertisements.
Government intervention is also required to ensure that
key national resources of objective therapeutic informa-
tion, such as the Australian Medicines Handbook and
Therapeutic Guidelines, are incorporated in prescribing
software. The provision of objective therapeutic informa-
tion is an important strategy of the QUM component of
Australian National Medicinal Drug Policy [27]. Ironi-
cally, while both the Australian Medicines Handbook and
Therapeutic Guidelines have been converted into elec-
tronic formats they are not yet included in computerised
prescribing software. The problems have included argu-
ments between software vendors and guideline producers
over who should pay for the integration and a lack of
defined standards for electronic information representa-
tion and interfacing.
More recently, the NPS RADAR project has shown the way
forward. RADAR provides independent information to
health professionals about medicines that have a new or a
changed listing on the PBS. RADAR drug monographs
have recently been incorporated in four leading GP pre-
scribing packages using an open standard interface. This
project has moved ahead because the Australian govern-
ment provided financial support to both the NPS and soft-
ware vendors to enable the RADAR integration to take
place.
Following a workshop on electronic decision support,
HL7 Australia has presented a work plan to the Australian
Health Information Council Electronic Decision Support
Steering Committee that would build on the RADAR
project by incorporating the Australian Medicines Hand-
book and Therapeutic Guidelines into clinical software in
a standard manner [28]. However, this plan has yet to pro-
ceed because of a current review of E-Health policy and
reorganisation of its governance [29].
The third area of prescribing software requiring govern-
ment intervention is standards for drug-drug interaction
checking. The NPS tested four popular GP software pack-
ages by entering a common set of elderly patients on mul-
tiple medications [30]. This revealed very different
behaviour by different software packages; some missed
serious drug-drug interactions, others produced numer-
ous trivial and clinical unimportant alerts. GPs noted that
the latter behaviour caused them to turn off all alerts [31].
There is an urgent need for standards concerning accepta-
ble drug-drug interaction detection &/or external assess-
ment of prescribing software, another item on the HL7
Australia work plan.
Conclusions
The PBS remained in the media and policy spotlight dur-
ing 2003–04. While the growth rate of the PBS has slowed
during the year under review the sustainability of the
Scheme remains an ongoing concern. One strategy
adopted by the government was to transfer more of theAustralia and New Zealand Health Policy 2005, 2:2 http://www.anzhealthpolicy.com/content/2/1/2
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cost of medicines to consumers through higher PBS co-
payments and increased safety-net thresholds. However,
such measures can result in higher costs elsewhere if
poorer patients forgo necessary medicines and end up
being hospitalised with uncontrolled disease.
Cost-shifting (and patient inconvenience) was reduced by
allowing State and Territory public hospitals limited
access to the PBS but these reforms also showed the need
for changes in the PBS to make it more suitable for hospi-
tal practice and the desirability of further integrating
health funding systems.
Educational strategies focusing on the quality use of PBS
medicines were successfully pursued but would benefit
from increased funding. In addition, there was an explor-
atory attempt to focus the attention of Divisions on PBS
costs by rewarding them with a moiety of any money
saved by their members through more cost-effective pre-
scribing. However, the difficulties experienced by the
EDQUM project in extracting useful drug utilisation data
from computerised prescribing systems highlighted the
need for prescribing software standards as did other prob-
lems with such software.
Information communication technology and information
management (ICT/IM) has the potential to allow individ-
ual health practitioners, Divisions and governments to
compare what is being done with what is recommended
best-practice, highlight major discrepancies, and provide
targeted education and appropriate incentives to reduce
the gap. However, as the events of 2003–04 show, this
potential is unlikely to be realised if the development of
clinical computer systems is left solely to market forces.
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